Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia

Inclusion Criteria: * Patient aged 18 and over, * With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy * Naive of any vulvovaginal treatment (surgery or radiotherapy) * No metastases * WHO \<or equal to 3 * Contraception method for women of childbearing potential * Patient affiliated to the social security scheme * Patient who understood, signed and dated the information note and the * consent form, * Patient able and willing to follow all study procedures in accordance with the protocol. Exclusion Criteria: * History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut * Ulceration or hyperpigmented lesions of the vulva * Patient with porphyria * Any previous vulvovaginal treatment (surgery or radiotherapy) * Metastatic disease * Patient undergoing treatment for any other invasive cancer * Pregnant, likely to be or breastfeeding patient * Patient deprived of liberty or under guardianship (including guardianship) * Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons. * Patient already included in another therapeutic trial with an experimental molecule, * Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure.